血液肿瘤贫血患者内源性促红细胞生成素水平与基因重组人促红细胞生成素应用研究

摘要

目的 探讨基因重组人促红细胞生成索(rhEPO)治疗血液肿瘤患者贫血的临床疗效及其和患者内源性血清促红细胞生成素(sEPO)水平关系.方法 采用化学发光法检测80例血液肿瘤贫血患者sEPO水平,对有治疗指征的患者给予rhEPO.结果 应用rhEPO治疗血液肿瘤缓解组患者的贫血,其效果明显优于血液肿瘤未缓解组患者;sEPO水平偏低者,应用rhEPO临床疗效较好.结论 血液肿瘤未缓解者sEPO水平高,红系造血功能缺陷,对rhEPO治疗反应差;而血液肿瘤缓解者sEPO水平趋于正常,骨髓红系造血功能恢复,应用rhEPO有效.%Objective To investigate the effect of recombinant human erythropoietin (rhEPO) in patients of hematologic malignancies with aneamia and its relationship of serum erythropoietin levels. Methods Serum EPO (sEPO) level in 80 patients with hematologic malignancies were detected by chemolumimiscence,and treated by recombinant human erythropoietin for patients with Hb<100 g/L. Results The effect on aneamia in tumor patients with remission were significantly higher than that with no-remission. The patients with lower level of sEPO had better respose to treatment by rhEPO than patients with higher level. Conclusion Higher level of sEPO in patients with no-remission hematopoietic tumor, with condition of marrow erythropoiesis aplasia, the effect of rhEPO was poor;, but sEPO level in patients with remission hematopoietic tumor were nearly normal with recovery of marrow erythropoiesis aplasia was effective by use of rhEPO.